With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

20190603 pipeline

 

Latest news

  • 11 Jul 2019

    Sensorion receives FDA IND approval for Arazasetron (SENS-401). Read

  • 01 Jul 2019

    Sensorion announces an oral presentation at the 5th congress of European ORL-Head & Neck Surgery in Brussels. Read

Patient center

Corporate presentation